PD-L1xVEGF Drug: 1st Global Data for SCLC from BioNTech
BioNTech and BMS reveal promising first global data for their new pd-l1xvegf drug, a novel bispecific antibody targeting Small Cell Lung Cancer (SCLC) patients.
SCLC
Read More
February 8, 2026